Showing results (121-130 of 133) with videos related to

Sort By:
Pageof 14
The Journal of Clinical Endocrinology and Metabolism|November 5, 2023
Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease ActivityRaymond S Douglas, Steven Couch, Sara T Wester, et al.
Nucleosides & Nucleotides|August 5, 1999
Gene therapy of cancer: activation of nucleoside prodrugs with E. coli purine nucleoside phosphorylaseJ A Secrist, W B Parker, P W Allan, et al.
Bioorganic & Medicinal Chemistry Letters|December 20, 2011
Novel substituted pyrimidines as HCV replication (replicase) inhibitorsCecil D Kwong, Jeremy L Clark, Anita T Fowler, et al.
The Journal of Bone and Joint Surgery. American Volume|January 7, 2021
Low Adherence to Recommended Guidelines for Open Fracture Antibiotic ProphylaxisCarol A Lin, Nathan N O'Hara, Sheila Sprague, et al.
Ophthalmology|October 24, 2021
Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X StudyRaymond S Douglas, George J Kahaly, Shoaib Ugradar, et al.
The New England Journal of Medicine|January 24, 2020
Teprotumumab for the Treatment of Active Thyroid Eye DiseaseRaymond S Douglas, George J Kahaly, Amy Patel, et al.
Bioorganic & Medicinal Chemistry Letters|July 21, 2012
Pyridofuran substituted pyrimidine derivatives as HCV replication (replicase) inhibitorsFrank Bennett, Hollis S Kezar, Vinay Girijavallabhan, et al.
Bioorganic & Medicinal Chemistry Letters|August 4, 2012
Synthesis and SAR of pyridothiazole substituted pyrimidine derived HCV replication inhibitorsVinay M Girijavallabhan, Carmen Alvarez, Frank Bennett, et al.
Pageof 14